<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335764</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00676</org_study_id>
    <secondary_id>NCI-2009-00676</secondary_id>
    <secondary_id>CDR0000476286</secondary_id>
    <secondary_id>NABTC-05-02</secondary_id>
    <secondary_id>NABTC-05-02</secondary_id>
    <secondary_id>U01CA137443</secondary_id>
    <nct_id>NCT00335764</nct_id>
  </id_info>
  <brief_title>Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma</brief_title>
  <official_title>Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib,
      and temsirolimus when given together with sorafenib and to see how well they work in treating
      patients with recurrent glioblastoma multiforme or gliosarcoma. Sorafenib, erlotinib,
      tipifarnib, and temsirolimus may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Sorafenib and tipifarnib may also stop the growth of tumor
      cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib,
      tipifarnib, or temsirolimus may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      Phase 1

      1. Determine the maximum tolerated dose (MTD) of tipifarnib, erlotinib hydrochloride, or
      temsirolimus in combination with a fixed dose of sorafenib in patients with recurrent
      glioblastoma multiforme or gliosarcoma who are not taking enzyme-inducing antiepileptic
      drugs.

      SECONDARY OBJECTIVES:

      Phase 1 and 2

        1. Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib,
           erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent
           glioblastoma multiforme or gliosarcoma.

        2. Characterize the pharmacokinetics of these doublet combinations, evaluating single-agent
           pharmacokinetics of each agent and the combination pharmacokinetics to determine
           drug-drug interactions.

      Phase 2

        1. Determine the efficacy of each of the doublet combinations, in terms of 6-month
           progression-free survival, in patients with recurrent glioblastoma multiforme or
           gliosarcoma.

        2. Determine the efficacy of each of the doublet combinations, in terms of 12-month
           survival and objective tumor response, in patients with recurrent glioblastoma
           multiforme or gliosarcoma.

      TERTIARY OBJECTIVES:

      Phase 2

        1. Perform exploratory correlative laboratory studies by examining tissue markers of signal
           transduction pathways by immunohistochemical analysis using tissue blocks obtained prior
           to initiation of protocol therapy, either from the time of diagnosis or subsequent tumor
           resection.

        2. Determine the relationship between tumor and blood biomarkers and clinical outcome of
           patients treated with the combination of targeted agents.

      OUTLINE:

      This is a multicenter, phase I, dose-escalation study of tipifarnib, erlotinib hydrochloride,
      and temsirolimus followed by a phase II open-label study.

      PHASE I:

      Patients are sequentially assigned to 1 of 3 treatment groups.

      GROUP 1: Patients receive oral sorafenib twice daily and oral erlotinib hydrochloride once
      daily on days 1-28.

      GROUP 2: Patients receive sorafenib as in group 1. Patients also receive temsirolimus IV over
      30 minutes on days 1, 8, 15, and 22.

      GROUP 3: Patients receive sorafenib as in group 1. Patients also receive oral tipifarnib
      twice daily on days 1-21.

      In all groups, treatment repeats every 28 days for up to 24 courses in the absence of disease
      progression or unacceptable toxicity.

      In each treatment group, cohorts of 3-6 patients receive escalating doses of erlotinib
      hydrochloride (group 1), temsirolimus (group 2), or tipifarnib (group 3) sequentially until
      the maximum tolerated dose (MTD) is determined for each group. The MTD is defined as the dose
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during
      the first course of therapy.

      PHASE II:

      Patients receive sorafenib as in phase I. Patients also receive erlotinib hydrochloride,
      temsirolimus, or tipifarnib as in phase I at the MTD determined in phase I.

      Tissue that was collected during a prior surgery is examined for biomarkers by
      immunohistochemistry (in patients enrolled in the phase II portion of the study). Biomarkers
      examined include epidermal growth factor receptor, Receptor tyrosine-protein kinase (HER-2),
      Protein kinase B (AKT), S6 ribosomal protein, and Receptor-linked tyrosine kinases (Erk).

      After completion of study treatment, patients are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>DLT defined as: any grade 4 hematologic toxicity; grade 3 thrombocytopenia &gt; 7 days, any grade 3/4 non-hematologic toxicity (despite maximal medical therapy), any intolerable grade 2 non-hematological, ro grade 3 hematological toxicity requiring deduction during first 28 days of treatment, any toxicity resulting in delay of &gt;1week during first 28 days of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Max Concentration (Cmax) of Group 2 Sorafenib and Temsirolimus (Phase I)</measure>
    <time_frame>cycle 1 ((Day1, Day15, Day28)</time_frame>
    <description>Group 2: 13 patients received temsirolimus 25mg IV and 7 patients treated with 200mg Sorafenib and 6 patients treated with 400mg Sorafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic cMax Group 1 Sorafenib and Erlotinib (Phase I)</measure>
    <time_frame>28days (D1, D15, D28) (0,1,2,4,6,8,12,24hr post administration)</time_frame>
    <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
13 total patients treated 100mg Erlotinib and either 200mg or 400mg of Sorafenib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic AUC 0-12 Group 1 Sorafenib and Erlotinib (Phase I)</measure>
    <time_frame>28Days (D1, D15, D28) (0,1,2,4,6,8,12,24hr post administration) AUC 0-12</time_frame>
    <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
16 patients Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference AUC - Area Under Curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration Group 2 Sorafenib and Temsirolimus (Phase I)</measure>
    <time_frame>15 days</time_frame>
    <description>Group 2: 12 patients were analyzed for Day 1 (1 patient not evaluable), 5 patients were analyzed for Day 15 (8 patients not evaluable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Time Curve (AUC) of Group 2 Sorafenib and Temsirolimus (Phase I)</measure>
    <time_frame>Cycle 1 (D1, D15, D28) (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
    <description>Day 1 = 12 patients (1 sample not evaluable) Day 15 = 5 patients (8 samples not evaluable)
AUC - Area Under Curve
8 samples collected over 24 hours - 28 day PKs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Cpmax Group 3 Sorafenib and Tipifarnib (Phase I) 100 mg QD (Level -1)</measure>
    <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
    <description>Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic CpMax Concentration of Group 3 Sorafenib and Tipifarnib (Phase I) 100mg BID</measure>
    <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
    <description>Group 3: patients were studied for their day 1 Cmax, and day 15 Cmax Tipifanib and Day 15 and Day 28 sorafenib
Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg QD (Level -1)</measure>
    <time_frame>Cycle 1 (D1, D15, D28) (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
    <description>Group 3: PKs for Dose level -1 100mg QD
Note that although 9 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg BID (Level 1)</measure>
    <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
    <description>Group 3: PKs for Dose level 1 Tipifarnib 100mg BID</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 Month Survival Rate (Phase II)</measure>
    <time_frame>12 months</time_frame>
    <description>number of patients alive at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>CTCAE 3.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase 2)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival at 6 Months (Phase II)</measure>
    <time_frame>6 months</time_frame>
    <description>Patients with a scan at 6 months without progressive disease Progressive disease defined as Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate in Patients With Measurable Disease (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression. Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Exploratory Correlative Laboratory Studies (Phase II)</measure>
    <time_frame>28 days</time_frame>
    <description>Examination of tissue markers of signal transduction pathways by immunohistochemical analysis this was an exploratory measure and it was not explore due to the negative results of the rest of the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular Targeted Combinations Correlative Study Initiative</measure>
    <time_frame>28 days</time_frame>
    <description>Determine the relationship between tumor and blood biomarkers and clinical outcome of patients this was more an exploratory correlative and was not completed due to the negative outcome of other parts of the study</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>given orally</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>given orally</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>given orally</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed intracranial glioblastoma multiforme or gliosarcoma

          -  Evidence of tumor progression by MRI or CT scan within the past 14 days AND on a
             steroid dose that has been stable for ≥ 5 days

          -  Patients who underwent prior therapy that included interstitial brachytherapy or
             stereotactic radiosurgery must have confirmation of true progressive disease rather
             than radiation necrosis by either positron emission tomography or thallium scanning,
             magnetic resonance (MR) spectroscopy, or surgical documentation of disease

          -  Recent resection of recurrent or progressive tumor allowed

          -  Residual disease is not required

          -  Treatment for any number of prior relapses, defined as disease progression after
             initial therapy (i.e., radiotherapy with or without chemotherapy if used as initial
             treatment), allowed (phase I)

          -  No more than 3 prior therapies (initial therapy and therapy for 2 relapses) (phase II)

          -  Each of the following is considered 1 relapse:

               -  Disease progression after initial therapy (i.e., radiotherapy with or without
                  chemotherapy if used as initial therapy)

               -  Underwent a surgical resection for relapsed disease and received no anticancer
                  therapy for up to 12 weeks after surgical resection AND then underwent a
                  subsequent surgical resection

               -  Received prior therapy for a low-grade glioma, followed by a surgical diagnosis
                  of glioblastoma

               -  Failed prior radiotherapy

          -  15 unstained paraffin slides or 1 tissue block must be available from original
             surgery, definitive surgery, or surgery closest to the initiation of this study (phase
             II)

          -  Karnofsky performance status 60-100%

          -  White Blood Cell (WBC) ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

          -  Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ≤ 2.5 times upper
             limit of normal (ULN)

          -  Total bilirubin normal

          -  Creatinine &lt; 1.5 mg/dL

          -  Prothrombin time (PT)/ international normalized ratio (INR) ≤ 1.5 (INR &lt; 3.0 for
             patients on anticoagulation therapy)

          -  INR &lt; 1.1 times upper limit of normal (ULN) (for patients on prophylactic
             anticoagulation therapy [low-dose warfarin])

          -  Fasting cholesterol &lt; 350 mg/dL (for patients receiving temsirolimus and sorafenib)

          -  Fasting triglycerides &lt; 400 mg/dL (for patients receiving temsirolimus and sorafenib)

          -  Well-controlled hypertension (e.g., systolic blood pressure ≤ 140 mm Hg or diastolic
             pressure ≤ 90 mm Hg) allowed

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for at least 2
             weeks (women) or 3 months (men) after completion of study treatment

          -  No peripheral neuropathy &gt; grade 1 (for patients receiving sorafenib and tipifarnib)

          -  No evidence of bleeding diathesis or coagulopathy

          -  No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of
             the cervix), unless in complete remission and off all therapy for that disease for ≥ 3
             years

          -  No significant traumatic injury within the past 21 days

          -  No active infection or serious medical illness that would preclude study treatment

          -  No condition that would impair ability to swallow pills (e.g., gastrointestinal tract
             disease resulting in an inability to take oral medication or a requirement for IV
             alimentation or active peptic ulcer disease)

          -  No HIV disease

          -  No allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole or econazole)
             or a history of allergic reactions attributed to any compound of similar chemical or
             biological composition to tipifarnib (for patients receiving sorafenib and tipifarnib)

          -  No other disease that would obscure toxicity or dangerously alter drug metabolism

          -  Recovered from prior therapy

          -  At least 7 days since prior noncytotoxic agents (e.g., interferon, tamoxifen,
             thalidomide, or isotretinoin) (radiosensitizer does not count)

          -  At least 14 days since prior vincristine

          -  At least 21 days since prior procarbazine or major surgery

          -  At least 28 days since prior investigational agent or cytotoxic therapy

          -  At least 42 days since prior nitrosoureas or radiotherapy

          -  No prior sorafenib, AEE788, or vatalanib

          -  No prior surgical procedures affecting absorption

          -  No prior tipifarnib, lonafarnib, or other agents targeting farnesyl transferase (for
             patients receiving sorafenib and tipifarnib)

          -  No prior temsirolimus or mechanistic target of rapamycin (mTOR-targeting agent) (phase
             II), rapamycin or everolimus, or Akt-pathway inhibitors (for patients receiving
             sorafenib and temsirolimus)

          -  No prior erlotinib hydrochloride, multitargeted human epidermal receptor (AEE788), or
             other epidermal growth factor receptor targeting agents (phase II) (for patients
             receiving sorafenib and erlotinib hydrochloride)

          -  No concurrent enzyme-inducing antiepileptic drugs (e.g., carbamazepine, oxcarbazepine,
             phenytoin, fosphenytoin, phenobarbital, or primidone)

          -  Dexamethasone allowed

          -  No concurrent hepatic cytochrome p450 enzyme-inducing anticonvulsants

          -  No other concurrent investigational agents or anticancer therapies, including
             chemotherapy, radiotherapy, hormonal therapy, or immunotherapy

          -  No concurrent prophylactic filgrastim (G-CSF) or other hematopoietic
             colony-stimulating factors

          -  Full-dose anticoagulants allowed provided both of the following criteria are met:

               -  In-range INR (between 2-3) on a stable dose of oral anticoagulant or on a stable
                  dose of low molecular weight heparin

               -  No active bleeding or pathological condition that carries a high risk of bleeding
                  (e.g., tumor involving major vessels or known varices)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <results_first_submitted>August 16, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients enrolled from 2006 - 2009 Patients accrued from comprehensive outpatient cancer centers</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Phase I Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally Dose Level 0: 200mg BID (fixed) Dose Level 1: 400mg BID (fixed)
erlotinib hydrochloride: given orally Dose Level 0: 100mg QD Dose Level 1: 100mg QD Dose Level 2: 150mg QD</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Phase I Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
temsirolimus: IV administration Dose Level 0: 25mg IV QW Dose Level 1: 25mg IV QW Dose Level 2: 50mg IV QW Dose Level 3: 75mg IV QW Dose Level 4: 125mg IV QW Dose Level 5: 175mg IV QW</description>
        </group>
        <group group_id="P3">
          <title>Group 3 Phase I Sorafenib and Tipifarnib</title>
          <description>Patients receive sorafenib tosylate BID as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
tipifarnib: given orally Dose Level 0: 100mg BID Dose Level 1: 100mg BID Dose Level 2: 200mg BID Dose Level 3: 300mg BID</description>
        </group>
        <group group_id="P4">
          <title>Group 1 Phase II Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
        </group>
        <group group_id="P5">
          <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally 400mg BID
temsirolimus: IV administration 25mg IV QW</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>wrong histology</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In Group 1 Phase 1 and Group 2 Phase 2 - each had a patient with wrong histology that made the patient ineligible and hence was not included in any of the analysis. Thus, total enrollment was 92 but only 90 evaluable patients</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Phase I Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Phase I Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
        </group>
        <group group_id="B3">
          <title>Group 3 Phase I Sorafenib and Tipifarnib</title>
          <description>Patients receive sorafenib tosylate as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally
tipifarnib: given orally</description>
        </group>
        <group group_id="B4">
          <title>Group 1 Phase II Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
        </group>
        <group group_id="B5">
          <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate 400 mg BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="36" upper_limit="70"/>
                    <measurement group_id="B2" value="50" lower_limit="32" upper_limit="59"/>
                    <measurement group_id="B3" value="57" lower_limit="27" upper_limit="76"/>
                    <measurement group_id="B4" value="52" lower_limit="30" upper_limit="76"/>
                    <measurement group_id="B5" value="50" lower_limit="24" upper_limit="64"/>
                    <measurement group_id="B6" value="53" lower_limit="24" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Scale</title>
          <description>Higher score better 100 normal no complaints/disease 90 capable normal activity few symptoms/disease 80 normal activity, some difficulty some symptoms/signs 70 caring for self not capable normal activity/work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care/help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures/treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="70" upper_limit="100"/>
                    <measurement group_id="B2" value="80" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B3" value="85" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B4" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B5" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B6" value="90" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I)</title>
        <description>DLT defined as: any grade 4 hematologic toxicity; grade 3 thrombocytopenia &gt; 7 days, any grade 3/4 non-hematologic toxicity (despite maximal medical therapy), any intolerable grade 2 non-hematological, ro grade 3 hematological toxicity requiring deduction during first 28 days of treatment, any toxicity resulting in delay of &gt;1week during first 28 days of treatment</description>
        <time_frame>28 days</time_frame>
        <population>3+3 design due to excessive toxicities of Group 3 no DLT was defined for Group 3</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase I Sorafenib and Erlotinib QD</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally Dose Level 0: 200mg BID (fixed) Dose Level 1: 400mg BID (fixed)
erlotinib hydrochloride: given orally Dose Level 0: 100mg QD Dose Level 1: 100mg QD Dose Level 2: 150mg QD</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase I Sorafenib and Temsirolimus QW</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
temsirolimus: IV administration Dose Level 0: 25mg IV QW Dose Level 1: 25mg IV QW Dose Level 2: 50mg IV QW Dose Level 3: 75mg IV QW Dose Level 4: 125mg IV QW Dose Level 5: 175mg IV QW</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Phase I Sorafenib and Tipifarnib BID</title>
            <description>Patients receive sorafenib tosylate BID as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
tipifarnib: given orally Dose Level 0: 100mg BID Dose Level 1: 100mg BID Dose Level 2: 200mg BID Dose Level 3: 300mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I)</title>
          <description>DLT defined as: any grade 4 hematologic toxicity; grade 3 thrombocytopenia &gt; 7 days, any grade 3/4 non-hematologic toxicity (despite maximal medical therapy), any intolerable grade 2 non-hematological, ro grade 3 hematological toxicity requiring deduction during first 28 days of treatment, any toxicity resulting in delay of &gt;1week during first 28 days of treatment</description>
          <population>3+3 design due to excessive toxicities of Group 3 no DLT was defined for Group 3</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="NA">due to the excessive toxicities of Group 3 no DLT was defined</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Max Concentration (Cmax) of Group 2 Sorafenib and Temsirolimus (Phase I)</title>
        <description>Group 2: 13 patients received temsirolimus 25mg IV and 7 patients treated with 200mg Sorafenib and 6 patients treated with 400mg Sorafenib</description>
        <time_frame>cycle 1 ((Day1, Day15, Day28)</time_frame>
        <population>Group 2: total 13 patients were studied for their day 1 Cmax ,day 15 Cmax and day 28 Cmax Note that although 13 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 Phase I Temsirolimus 25mg QW</title>
            <description>Pt receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients receive sorafenib tosylate BID.
sorafenib tosylate: given orally
temsirolimus: IV administration 25mg</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase I Sorafenib 200mg BID</title>
            <description>Patients receive sorafenib tosylate BID 200mg. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally 200mg
temsirolimus: IV administration 25mg</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Phase I Sorafenib 400mg BID</title>
            <description>Patients receive sorafenib tosylate BID 400mg. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally 400mg
temsirolimus: IV administration 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Max Concentration (Cmax) of Group 2 Sorafenib and Temsirolimus (Phase I)</title>
          <description>Group 2: 13 patients received temsirolimus 25mg IV and 7 patients treated with 200mg Sorafenib and 6 patients treated with 400mg Sorafenib</description>
          <population>Group 2: total 13 patients were studied for their day 1 Cmax ,day 15 Cmax and day 28 Cmax Note that although 13 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530" spread="101"/>
                    <measurement group_id="O2" value="NA" spread="NA">specimens not collected on day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">specimens not collected on day 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616" spread="209"/>
                    <measurement group_id="O2" value="4.04" spread="1.68"/>
                    <measurement group_id="O3" value="7.49" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">specimens not collected on day 28</measurement>
                    <measurement group_id="O2" value="3.26" spread="1.34"/>
                    <measurement group_id="O3" value="6.24" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic cMax Group 1 Sorafenib and Erlotinib (Phase I)</title>
        <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
13 total patients treated 100mg Erlotinib and either 200mg or 400mg of Sorafenib</description>
        <time_frame>28days (D1, D15, D28) (0,1,2,4,6,8,12,24hr post administration)</time_frame>
        <population>8 samples collected over 24 hours on Day 1, day 15 and day 28 (0,1,2,4,6,8,12hr, &amp; 24hr post administration). Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase I Erlotinib 100mg QD</title>
            <description>Patients receive oral oral erlotinib hydrochloride 100 mg once daily on days 1-28. Pts also receive Sorafenib tosylate BID
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Phase I Sorafenib 200mg BID</title>
            <description>Patients receive oral sorafenib tosylate BID 200mg oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally 200mg
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Phase I Sorafenib 400mg BID</title>
            <description>Patients receive oral sorafenib tosylate BID 400mg and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally 400mg
erlotinib hydrochloride: given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic cMax Group 1 Sorafenib and Erlotinib (Phase I)</title>
          <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
13 total patients treated 100mg Erlotinib and either 200mg or 400mg of Sorafenib</description>
          <population>8 samples collected over 24 hours on Day 1, day 15 and day 28 (0,1,2,4,6,8,12hr, &amp; 24hr post administration). Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cMax Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="155"/>
                    <measurement group_id="O2" value="NA" spread="NA">Specimens not collected/drug not given on Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Specimens not collected/drug not given on Day 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cMax Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662" spread="373"/>
                    <measurement group_id="O2" value="5.51" spread="2.68"/>
                    <measurement group_id="O3" value="8.4" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cMax Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653" spread="469"/>
                    <measurement group_id="O2" value="4.67" spread="2.10"/>
                    <measurement group_id="O3" value="4.10" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic AUC 0-12 Group 1 Sorafenib and Erlotinib (Phase I)</title>
        <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
16 patients Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference AUC - Area Under Curve</description>
        <time_frame>28Days (D1, D15, D28) (0,1,2,4,6,8,12,24hr post administration) AUC 0-12</time_frame>
        <population>8 samples collected over 24 hours on Day 1, day 15 and day 28 AUC 0-12 16 patients treated at 100mg erlotinib,and Sorafenib at either 200 or 400mg Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase I Erlotinib 100mg QD</title>
            <description>Patients receive oral erlotinib hydrochloride 100 mg once daily on days 1-28.And also oral sorafenib tosylate BID
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Phase I Sorafenib 200mg</title>
            <description>Patients receive oral sorafenib tosylate BID 200mg and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally 200mg
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O3">
            <title>Group 1 Phase I Sorafenib 400mg</title>
            <description>Patients receive oral sorafenib tosylate BID 400mg and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally 400mg
erlotinib hydrochloride: given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic AUC 0-12 Group 1 Sorafenib and Erlotinib (Phase I)</title>
          <description>8 samples collected over 24 hours on Day 1, day 15 and day 28
16 patients Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference AUC - Area Under Curve</description>
          <population>8 samples collected over 24 hours on Day 1, day 15 and day 28 AUC 0-12 16 patients treated at 100mg erlotinib,and Sorafenib at either 200 or 400mg Note that although 16 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
          <units>ug xhr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-12 Day1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.61"/>
                    <measurement group_id="O2" value="NA" spread="NA">Specimens not collected/drug not given on Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Specimens not collected/drug not given on Day 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-12 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="4.59"/>
                    <measurement group_id="O2" value="45.85" spread="21.5"/>
                    <measurement group_id="O3" value="62.4" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-12 Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="4.05"/>
                    <measurement group_id="O2" value="40.29" spread="18.6"/>
                    <measurement group_id="O3" value="38.7" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Concentration Group 2 Sorafenib and Temsirolimus (Phase I)</title>
        <description>Group 2: 12 patients were analyzed for Day 1 (1 patient not evaluable), 5 patients were analyzed for Day 15 (8 patients not evaluable)</description>
        <time_frame>15 days</time_frame>
        <population>Group 2: 12 patients were analyzed for Day 1, 5 patients were analyzed for Day 15. In both cases samples were either missing or not enough to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 Phase I Sorafenib and Temsirolimus QW</title>
            <description>Patients receive sorafenib tosylate BID Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration Group 2 Sorafenib and Temsirolimus (Phase I)</title>
          <description>Group 2: 12 patients were analyzed for Day 1 (1 patient not evaluable), 5 patients were analyzed for Day 15 (8 patients not evaluable)</description>
          <population>Group 2: 12 patients were analyzed for Day 1, 5 patients were analyzed for Day 15. In both cases samples were either missing or not enough to analyze.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Time Curve (AUC) of Group 2 Sorafenib and Temsirolimus (Phase I)</title>
        <description>Day 1 = 12 patients (1 sample not evaluable) Day 15 = 5 patients (8 samples not evaluable)
AUC - Area Under Curve
8 samples collected over 24 hours - 28 day PKs</description>
        <time_frame>Cycle 1 (D1, D15, D28) (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
        <population>13 patients temsirolimus 25mg and Sorafenib at either 200mg or 400mg. 1 patient withdrew early hence specimens not analyzed in other cases samples were either missing or not enough to analyze if numbers are not 12</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2 Phase I Temsirolimus 25mg QW</title>
            <description>Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive sorafenib tosylate BID
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
temsirolimus: IV administration Dose Level 0: 25mg IV QW Dose Level 1: 25mg IV QW</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase I Sorafenib 200mg</title>
            <description>Patients receive sorafenib tosylate BID Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally Dose Level 0: 200mg BID
temsirolimus: IV administration Dose Level 0: 25mg IV QW Dose Level 1: 25mg IV QW</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Phase I Sorafenib 400mg</title>
            <description>Patients receive sorafenib tosylate BID Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally Dose Level 1: 400mg BID
temsirolimus: IV administration Dose Level 0: 25mg IV QW Dose Level 1: 25mg IV QW</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Time Curve (AUC) of Group 2 Sorafenib and Temsirolimus (Phase I)</title>
          <description>Day 1 = 12 patients (1 sample not evaluable) Day 15 = 5 patients (8 samples not evaluable)
AUC - Area Under Curve
8 samples collected over 24 hours - 28 day PKs</description>
          <population>13 patients temsirolimus 25mg and Sorafenib at either 200mg or 400mg. 1 patient withdrew early hence specimens not analyzed in other cases samples were either missing or not enough to analyze if numbers are not 12</population>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.27"/>
                    <measurement group_id="O2" value="NA" spread="NA">Samples not collected on this day, drug not given on day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Samples not collected on this day, drug not given on day 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.28"/>
                    <measurement group_id="O2" value="35.45" spread="18.10"/>
                    <measurement group_id="O3" value="42.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples not collected on this day, drug not given on day 28</measurement>
                    <measurement group_id="O2" value="29.0" spread="12.32"/>
                    <measurement group_id="O3" value="32.98" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Cpmax Group 3 Sorafenib and Tipifarnib (Phase I) 100 mg QD (Level -1)</title>
        <description>Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
        <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
        <population>Group 3: Only PKs for Dose level 1 and -1 were collected. Note that although 6 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 Phase I Tipifarnib 100mg QD</title>
            <description>Patients receive oral tipifarnib every day on days 1-21. Patients also receive sorafenib tosylate BID
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose level -1: 100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Group 3 Phase I Sorafenib 200mg BID</title>
            <description>Patients receive sorafenib tosylate BID Patients also receive oral tipifarnib every day on days 1-21.
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose level -1: 100mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Cpmax Group 3 Sorafenib and Tipifarnib (Phase I) 100 mg QD (Level -1)</title>
          <description>Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
          <population>Group 3: Only PKs for Dose level 1 and -1 were collected. Note that although 6 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.5" spread="135.85"/>
                    <measurement group_id="O2" value="NA" spread="NA">Samples not collected on day 1, drug not given on day 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.5" spread="186"/>
                    <measurement group_id="O2" value="3.34" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples not collected on day 28, drug not given on day 28</measurement>
                    <measurement group_id="O2" value="3.43" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic CpMax Concentration of Group 3 Sorafenib and Tipifarnib (Phase I) 100mg BID</title>
        <description>Group 3: patients were studied for their day 1 Cmax, and day 15 Cmax Tipifanib and Day 15 and Day 28 sorafenib
Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
        <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
        <population>Group 3: patients were studied for their day 1 Cmax, day 15 Cmax. and Day 28 Cmax PKs for 100mg BID Tipifarnib Note that although 10 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference
Level 1 (n=10): Day 1 n=6 (4 samples not evaluable) and D15 n=5 (5 samples not evaluable)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 Phase I Tipifarnib 100mg BID</title>
            <description>Patients receive oral tipifarnib 100mg twice daily on days 2-21. Patients also sorafenib tosylate BID 200mg
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level 1: 100mg BID</description>
          </group>
          <group group_id="O2">
            <title>Group 3 Phase I Sorafenib 200mg BID</title>
            <description>Patients receive oral tipifarnib 100mg twice daily on days 2-21. Patients also sorafenib tosylate BID 200mg
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level 1: 100mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic CpMax Concentration of Group 3 Sorafenib and Tipifarnib (Phase I) 100mg BID</title>
          <description>Group 3: patients were studied for their day 1 Cmax, and day 15 Cmax Tipifanib and Day 15 and Day 28 sorafenib
Group 3: Only PKs for Dose level 1 and -1 were collected.</description>
          <population>Group 3: patients were studied for their day 1 Cmax, day 15 Cmax. and Day 28 Cmax PKs for 100mg BID Tipifarnib Note that although 10 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference
Level 1 (n=10): Day 1 n=6 (4 samples not evaluable) and D15 n=5 (5 samples not evaluable)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.17" spread="65.96"/>
                    <measurement group_id="O2" value="NA" spread="NA">Samples not collected on this day, drug not given</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.60" spread="84.83"/>
                    <measurement group_id="O2" value="4.17" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples not collected on this day, drug not given</measurement>
                    <measurement group_id="O2" value="4.53" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg QD (Level -1)</title>
        <description>Group 3: PKs for Dose level -1 100mg QD
Note that although 9 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</description>
        <time_frame>Cycle 1 (D1, D15, D28) (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
        <population>Group 3: PKs for Dose level -1 Tipifarnib 100mg QD Sorafenib started day 2</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 Phase I Tipifarnib 100mg QD</title>
            <description>Patients receive oral tipifarnib 100mg twice daily on days 1-21. also receive sorafenib tosylate BID100mg
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level -1: 100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Group 3 Phase I Sorafenib 200mg BID</title>
            <description>Patients receive sorafenib tosylate BID100mgal and also tipifarnib 100mg QD on days 1-21.sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level -1: 100mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg QD (Level -1)</title>
          <description>Group 3: PKs for Dose level -1 100mg QD
Note that although 9 patients were accrued/analyzed some samples were incomplete or inevaluable or missing hence number analyzed difference</description>
          <population>Group 3: PKs for Dose level -1 Tipifarnib 100mg QD Sorafenib started day 2</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="814.5" spread="347.57"/>
                    <measurement group_id="O2" value="NA" spread="NA">Samples not collected on this day, drug not given</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706" spread="644.88"/>
                    <measurement group_id="O2" value="30.59" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples not collected on this day, drug not given</measurement>
                    <measurement group_id="O2" value="41.43" spread="28.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg BID (Level 1)</title>
        <description>Group 3: PKs for Dose level 1 Tipifarnib 100mg BID</description>
        <time_frame>Cycle 1 = 28 day PKs D1, D15,D28 (0,1,2,4,6,8,12,24hr post drug administration)</time_frame>
        <population>Group 3: PKs for Dose level 1 Tipifarnib 100mg BID</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3 Phase I Tipifarnib 100mg QD</title>
            <description>Patients receive oral tipifarnib twice daily on days 1-21. Patients also receive sorafenib tosylate BID 200 mg starting on day 2
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level 1: 100mg BID</description>
          </group>
          <group group_id="O2">
            <title>Group 3 Phase I Sorefenib 200mg BID</title>
            <description>Patients also receive sorafenib tosylate BID 200 mg starting on day 2. Patients receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally Dose Level 0: 200mg BID
tipifarnib: given orally Dose Level 1: 100mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg BID (Level 1)</title>
          <description>Group 3: PKs for Dose level 1 Tipifarnib 100mg BID</description>
          <population>Group 3: PKs for Dose level 1 Tipifarnib 100mg BID</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631.67" spread="431.12"/>
                    <measurement group_id="O2" value="NA" spread="NA">Samples not collected, drug not given on this day</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.25" spread="758.07"/>
                    <measurement group_id="O2" value="12.17" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Samples not collected, drug not given on this day</measurement>
                    <measurement group_id="O2" value="36.45" spread="17.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12 Month Survival Rate (Phase II)</title>
        <description>number of patients alive at 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Group 3 did not reach an MTD Hence, did not complete the Phase 2 portion of study, combination treatment too toxic.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Survival Rate (Phase II)</title>
          <description>number of patients alive at 12 months</description>
          <population>Group 3 did not reach an MTD Hence, did not complete the Phase 2 portion of study, combination treatment too toxic.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients Alive at 12 Months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients Dead at 12 Months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase I)</title>
        <description>CTCAE 3.0</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase I Sorafenib and Erlotinib QD</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase I Sorafenib and Temsirolimus QW</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Phase I Sorafenib and Tipifarnib BID</title>
            <description>Patients receive sorafenib tosylate BID as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally
tipifarnib: given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase I)</title>
          <description>CTCAE 3.0</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukopenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, SGOT Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemmorrhoids Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertriglyceridemia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint - Knee Pain Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/thrombus/embolism Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysphasia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Head/Headache Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Encephalopathy Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, SGPT Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase 2)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase 2)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphopenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (high) Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (high) Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharyngeal mucositis Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizures Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 6 Months (Phase II)</title>
        <description>Patients with a scan at 6 months without progressive disease Progressive disease defined as Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
        <time_frame>6 months</time_frame>
        <population>Group 3 did not reach an MTD not complete the Phase 2 portion of study, combination treatment too toxic. End points not followed for group 3 Phase 2</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Phase I Sorafenib and Tipifarnib BID</title>
            <description>Patients receive sorafenib tosylate BID as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally Dose Level 0: 200mg BID Dose Level 1: 400mg BID
tipifarnib: given orally Dose Level 0: 100mg BID Dose Level 1: 100mg BID Dose Level 2: 200mg BID Dose Level 3: 300mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months (Phase II)</title>
          <description>Patients with a scan at 6 months without progressive disease Progressive disease defined as Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
          <population>Group 3 did not reach an MTD not complete the Phase 2 portion of study, combination treatment too toxic. End points not followed for group 3 Phase 2</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O3" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate in Patients With Measurable Disease (Phase II)</title>
        <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression. Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in Patients With Measurable Disease (Phase II)</title>
          <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression. Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Correlative Laboratory Studies (Phase II)</title>
        <description>Examination of tissue markers of signal transduction pathways by immunohistochemical analysis this was an exploratory measure and it was not explore due to the negative results of the rest of the study</description>
        <time_frame>28 days</time_frame>
        <population>this was more an exploratory correlative and as per the pre-specified protocol, was only to be performed if the outcome of other parts of the study indicated positive results.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Correlative Laboratory Studies (Phase II)</title>
          <description>Examination of tissue markers of signal transduction pathways by immunohistochemical analysis this was an exploratory measure and it was not explore due to the negative results of the rest of the study</description>
          <population>this was more an exploratory correlative and as per the pre-specified protocol, was only to be performed if the outcome of other parts of the study indicated positive results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Molecular Targeted Combinations Correlative Study Initiative</title>
        <description>Determine the relationship between tumor and blood biomarkers and clinical outcome of patients this was more an exploratory correlative and was not completed due to the negative outcome of other parts of the study</description>
        <time_frame>28 days</time_frame>
        <population>This was more an exploratory correlative and as per the pre-specified protocol, was only to be performed if the outcome of other parts of the study indicated positive results.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Phase II Sorafenib and Erlotinib</title>
            <description>Patients receive oral sorafenib tosylate BID and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
            <description>Patients receive sorafenib tosylate BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Molecular Targeted Combinations Correlative Study Initiative</title>
          <description>Determine the relationship between tumor and blood biomarkers and clinical outcome of patients this was more an exploratory correlative and was not completed due to the negative outcome of other parts of the study</description>
          <population>This was more an exploratory correlative and as per the pre-specified protocol, was only to be performed if the outcome of other parts of the study indicated positive results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>CTCAE</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Phase I Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Phase I Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
        </group>
        <group group_id="E3">
          <title>Group 3 Phase I Sorafenib and Tipifarnib</title>
          <description>Patients receive sorafenib tosylate as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21.
sorafenib tosylate: given orally
tipifarnib: given orally</description>
        </group>
        <group group_id="E4">
          <title>Group 1 Phase II Sorafenib and Erlotinib</title>
          <description>Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
sorafenib tosylate: given orally
erlotinib hydrochloride: given orally</description>
        </group>
        <group group_id="E5">
          <title>Group 2 Phase II Sorafenib and Temsirolimus</title>
          <description>Patients receive sorafenib tosylate 400 mg BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1, 8, 15, and 22.
sorafenib tosylate: given orally
temsirolimus: IV administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pancrease infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Generalized Muscle Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to combo toxicities for Sorafenib and Tipifarnib exceeding monotherapy for each, MTD was not determined nor was Phase 2 explored.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Gilbert, MD</name_or_title>
      <organization>Adult Brain Tumor Consortium (ABTC)</organization>
      <phone>410-955-3657</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

